Please login to the form below

Not currently logged in
Email:
Password:

Asian patient groups give pharma above average marks for reputation

PatientView survey finds 49% believe sector has a good corporate reputation

PatientViewAsian patient groups have an above average impression of pharmaceutical companies, according to a new report.

New data from PatientView’s established corporate reputation survey show 49% of patient groups in Asia believe the sector has an ‘excellent’ or ‘good’ corporate reputation.

The figures, drawn from 98 patient groups from Australasia, Central Asia, East Asia, South Asia and South-East Asia, present a rosier picture than their counterparts from around the world, 37% of which held the same view.

PatientView’s 2016 Corporate Reputation of Pharma Companies survey covers the efforts of 16 global pharma companies including Pfizer - which was ranked the most familiar to the Asian patient groups.

Respondents also ranked AbbVie as overall first for corporate reputation among the groups familiar with the firm. The US company ranked first for patient-centricity, transparency and patient-group relations as well.

Meanwhile, GSK was placed first for the provision of ‘high-quality’ patient information and Novo Nordisk took first position for patient safety, high quality products and integrity.

Article by
Gemma Jones

16th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics